1-(2-甲基苯基)-环丙胺 | 503417-29-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(2-甲基苯基)-环丙胺
• 中文别名: 1-(2-甲基苯基)环丙胺
• 英文名称: 1-(2'-methylphenyl)cyclopropylamine
• 英文别名: 1-(2-Methylphenyl)cyclopropanamine；1-(2-methylphenyl)cyclopropan-1-amine
• CAS: 503417-29-6
• 化学式: C₁₀H₁₃N
• 分子量: 147.22
• InChiKey: FDPOMQRUQMOUTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  5-(2-(dimethylamino)ethoxy)-2-methylbenzoic acid hydrochloride 、 1-(2-甲基苯基)-环丙胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 盐酸 作用下， 以 二氯甲烷 、 水 、 乙腈 为溶剂， 以15 %的产率得到5-(2-(dimethylamino)ethoxy)-2-methyl-N-(1-(o-tolyl)cyclopropyl)benzamide hydrochloride
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES
  [FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DES CORONAVIRUS

  摘要：

  This invention provides compounds for the inhibition of papain-like proteases (PLpros) for the inhibition of viruses, including compounds of formula (I"), and pharmaceutically acceptable salts thereof.

  公开号：

  WO2023064493A1
• 作为产物：
  描述：

  邻甲基苯腈 、 diethylzinc 在 METHYLTITANIUM TRIISOPROPOXIDE 、 lithium isopropoxide 、 lithium iodide 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 以54%的产率得到1-(2-甲基苯基)-环丙胺
  参考文献：
  名称：

  Primary 1-Arylcyclopropylamines from Aryl Cyanides with Diethylzinc and Titanium Alkoxides

  摘要：

  [GRAPHICS]1-Aryl-substituted primary cyclopropylamines are conveniently prepared from aromatic nitriles and diethylzinc. The yields range from 40 to 56% for donor-substituted (five examples) to 62-82% for non- and acceptor-substituted substrates (nine examples).

  DOI：

  10.1021/ol034021k

文献信息

• Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists
  申请人：Cook Brian Nicholas

  公开号：US20120270870A1

  公开（公告）日：2012-10-25

  Diclosed are CCR1 receptor antagonists of the formula (I) wherein Ar 1 , Ar 2 , R 1 , X and G are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).

  本发明公开了式(I)的CCR1受体拮抗剂，其中Ar1、Ar2、R1、X和G在此公开。还公开了式(I)化合物的组合物、制备方法和使用方法。
• CANNABINOID RECEPTOR MODULATORS
  申请人：Jones Robert M.

  公开号：US20120214766A1

  公开（公告）日：2012-08-23

  The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.

  本发明涉及公式Ia的某些化合物及其制药组合物，其调节大麻素CB2受体的活性。本发明还涉及公式Ia的某些化合物及其制药组合物，其调节CB1受体和CB2受体的活性。本发明的化合物和制药组合物适用于治疗以下疾病的方法：疼痛，例如骨骼和关节疼痛，肌肉疼痛，牙痛，偏头痛和其他头痛，炎性疼痛，神经痛，由治疗副作用引起的疼痛和与骨关节炎相关的疼痛；过敏症；炎性过敏症；神经病性过敏症；急性疼痛感受；骨质疏松症；多发性硬化症相关痉挛；自身免疫疾病；过敏反应；中枢神经系统炎症；动脉粥样硬化；不良的免疫细胞活动和炎症；年龄相关的黄斑变性；咳嗽；白血病；淋巴瘤；中枢神经系统肿瘤；前列腺癌；阿尔茨海默病；中风引起的损伤；痴呆症；肌萎缩性侧索硬化症和帕金森病。
• Piperdine CXCR7 receptor modulators
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：US10752620B2

  公开（公告）日：2020-08-25

  The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2 and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

  本发明涉及式 (I) 的哌啶衍生物 其中 Ar1、Ar2、RAr1、R1、R2 和 R3 如描述中所述，它们的制备，它们的药学上可接受的盐，以及它们作为药物的用途，含有一种或多种式 (I) 化合物的药物组合物，特别是它们作为 CXCR7 受体调节剂的用途。
• Cannabinoid receptor modulators
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US11214548B2

  公开（公告）日：2022-01-04

  The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.

  本发明涉及某些调节大麻素 CB2 受体活性的式 Ia 化合物及其药物组合物。本发明还涉及某些能调节 CB1 受体和 CB2 受体活性的式 Ia 化合物及其药物组合物。本发明的化合物及其药物组合物用于治疗以下疾病的方法：疼痛，例如骨痛和关节痛、肌肉痛、牙痛、偏头痛和其他头痛、炎症性疼痛、神经性疼痛、作为治疗药物的不良反应出现的疼痛以及与骨关节炎相关的疼痛；痛觉减退；异动症；炎症性痛觉减退；神经性痛觉减退；急性痛觉；骨质疏松症；多发性硬化症相关的痉挛、自身免疫性疾病、过敏反应、中枢神经系统炎症、动脉粥样硬化、不想要的免疫细胞活性和炎症、老年性黄斑变性、咳嗽、白血病、淋巴瘤、中枢神经系统肿瘤、前列腺癌、阿尔茨海默病、中风引起的损伤、痴呆、肌萎缩性脊髓侧索硬化症和帕金森病。
• INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2491028B1

  公开（公告）日：2013-12-11